[Reduction of regurgitation in aortic and mitral insufficiency by captopril in acute and long-term trials].
Afterload reduction is an accepted therapeutic principle in the management of acute aortic (Ai) and mitral insufficiency (Mi). The question whether acute and chronic converting-enzyme inhibition by captopril has a beneficial hemodynamic effect in chronic Ai and Mi has been investigated in 17 patients with Ai and 10 with Mi. Ejection and regurgitation fraction (RF) were measured by radionuclide ventriculography (RNV) before, after 25 mg captopril and after 3-5 months of long-term treatment. The humoral response of the renin-angiotensin system (RAS) was quantified by analysis of angiotensin I and II. Captopril lowered under acute and chronic treatment RF in Ai and Mi by 32%. Angiotensin II levels decreased by the same order of magnitude. Acute and chronic vasodilation was followed by a distinct but well tolerated fall in blood pressure, especially in patients with Mi. These favourable hemodynamic effects of captopril make this therapy an adjunct but not an alternative to valve replacement.
D001022:Aortic Valve Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D002216:Captopril / Q000627:therapeutic use*; D006439:Hemodynamics; D006801:Humans; D008944:Mitral Valve Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D002216:Captopril
Reduktion der Regurgitation bei Aorten- und Mitralinsuffizienz durch Captopril im Akut- und Langzeitversuch.